Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taxifolin for Prevention of Cognitive Impairment (T-COG)
jRCTs051250004Recruiting
- Sponsor
- Towa Pharmaceutical Co., Ltd.
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of taxifolin in Mild Cognitive Impairment (MCI) and Dementia (2 arms), sponsored by Towa Pharmaceutical Co., Ltd. Primary endpoint: Primary: Change in MoCA total score from baseline to 12 weeks (extraction). Started May 2025; status: recruiting.
02
Drugs
taxifolin
03
Conditions
Mild Cognitive Impairment (MCI)Dementia
Beyond the preview
Go deeper on jRCTs051250004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051250004.